{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"description":"Number of patients with relapsed disease within 1 Year post-transplant. Relapse is defined as the detection of \\> 5% blasts after a documented complete remission.","groups":[{"description":"See Detailed Description\n\nCyclosporine: Given IV or PO\n\nDasatinib: Given PO\n\nFludarabine Phosphate: Given IV\n\nImatinib Mesylate: Given PO\n\nMycophenolate Mofetil: Given PO\n\nNilotinib: Given PO\n\nNonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Undergo nonmyeloablative allogeneic PBSC transplantation\n\nPeripheral Blood Stem Cell Transplantation: Undergo allogeneic PBSC transplantation\n\nTherapeutic Allogeneic Lymphocytes: Given IV\n\nTotal-Body Irradiation: Undergo TBI","id":"OG000","title":"Treatment (Allogeneic Nonmyeloablative HSCT)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Assessed up to 1 year","title":"Relapse Free Survival","type":"PRIMARY","unitOfMeasure":"Participants"}